Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of TX200-TR101 CAR-Treg kidney transplant recipients
2022-002440-40Phase 2Terminated
- Sponsor
- Sangamo Therapeutics
- Start
- Dec 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TX200 in kidney allograft rejection, sponsored by Sangamo Therapeutics. Primary endpoints: Long-term safety and tolerability of TX200-TR101 and Long-term graft-related outcomes. Started Dec 2022; status: terminated.
02
Drugs
TX200
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2022-002440-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002440-40.